Accounting Methods and Revenue Recognition - The company adjusts the accounting method for remaining equity after losing control of a subsidiary, either using the equity method or recognizing the difference between fair value and book value as current profit or loss[1] - Revenue from export sales is recognized based on the trade terms, with different recognition points for various trade settlement methods such as CIF, FOB, and DDP[5] - Revenue from domestic sales is recognized upon delivery to the customer's specified location and customer confirmation of receipt[9] Asset Management and Impairment - Construction in progress is recognized when economic benefits are likely to flow in and costs can be reliably measured, and is transferred to fixed assets upon reaching the intended usable state[2] - The company reviews the useful life and amortization method of finite-lived intangible assets annually, adjusting estimates and recognizing impairment if future economic benefits are no longer expected[4] - The company assesses impairment of assets related to contract costs, recognizing impairment losses if the carrying amount exceeds the expected remaining consideration minus estimated costs[10] - The company's intangible assets have a book value of 192,311,293.45 RMB at the end of the period, with a cumulative amortization of 20,669,830.54 RMB[34] - The company's engineering materials have a book value of 82,350,552.80 RMB at the end of the period, with a provision for impairment of 721,797.20 RMB[28] Government Grants and Subsidies - Government grants are recognized upon receipt, with specific criteria for recognizing grants based on expected amounts and compliance with fiscal support policies[7] - Government subsidies are recognized as deferred income and amortized over the useful life of related assets, with any remaining balance transferred to profit or loss upon disposal of the assets[11] - The company's deferred tax assets at the end of the period were RMB 85,304,542.97, with a significant portion coming from government subsidies of RMB 58,661,705.01[39][40] - Total government subsidies received increased to 138,021,872.10 RMB from 29,916,370.85 RMB, a significant growth of 361.4%[67] Financial Assets and Liabilities - The company holds no financial assets measured at fair value through profit or loss as of the reporting period, compared to RMB 230 million at the beginning of the period[13] - Bank acceptance bills amounted to RMB 50.49 million at the end of the period, all of which were not derecognized[14] - The balance of bank acceptance notes was RMB 53.29 million at the end of the period, with no bad debt provision[15] - The company's financial assets and liabilities not measured at fair value have a book value close to their fair value[169] - The fair value of receivables financing at the end of the period is RMB 3,292,184.01, classified under Level 2 fair value measurement[166] Inventory and Cost Management - Inventory increased from RMB 4.56 million to RMB 13.67 million, with significant growth in work-in-progress and finished goods[20] - Raw materials inventory decreased from RMB 83.18 million to RMB 39.66 million, while finished goods inventory increased from RMB 198.48 million to RMB 307.34 million[23] - The total inventory balance at the end of the period was RMB 492.63 million, with a provision for inventory impairment of RMB 13.67 million[23] - Operating costs decreased by 19.71% to RMB 1,161,708,799.37, primarily due to lower raw material prices and reduced manufacturing expenses[183][184] Project Investments and Progress - The budget for the Vitamin B5 project is 460,021,300 RMB, with a cumulative investment of 75.44% of the budget, and the project progress is 75.44%[25] - The Vitamin A project has a budget of 781,291,500 RMB, with a cumulative investment of 25.40% of the budget, and the project progress is 25.40%[25] - The Enterprise Research Institute project has a budget of 128,865,500 RMB, with a cumulative investment of 69.20% of the budget, and the project progress is 69.20%[25] - The fine chemical project has a budget of 500,000,000 RMB, with a cumulative investment of 2.95% of the budget, and the project progress is 2.95%[25] - The Le Ping Industrial Park cogeneration project has a budget of 350,000,000 RMB, with a cumulative investment of 12.07% of the budget, and the project progress is 12.07%[25] - The other fine chemical product project has a budget of 3,690,000,000 RMB, with a cumulative investment of 5.80% of the budget, and the project progress is 5.80%[25] - The Qingtongxia Industrial Park thermal power island project has a budget of 1,464,730,000 RMB, with a cumulative investment of 2.71% of the budget, and the project progress is 2.71%[25] - The total budget for all projects is 7,374,908,300 RMB, with a cumulative investment of 342,940,892.04 RMB[25] Financial Performance and Metrics - The company's total revenue for the year 2023 was RMB 1,881,993,019.35, with a cost of RMB 1,161,708,799.37, resulting in a gross profit of RMB 720,284,219.98[50] - B-vitamins contributed the majority of the revenue, generating RMB 1,650,309,734.61, with a cost of RMB 958,705,177.48[52] - Domestic sales accounted for RMB 782,140,234.10, while international sales contributed RMB 1,099,852,785.25[52] - The company's net profit for the current period was 475,853,298.64 RMB, a decrease from the previous period's 622,115,124.53 RMB[98] - Revenue for 2023 was 1,881,993,019.35 yuan, a decrease of 18.34% compared to the previous year[120] - Net profit attributable to shareholders was 475,853,298.64 yuan, down 23.51% year-on-year[120] - Operating cash flow increased by 20.21% to 729,212,499.59 yuan[120] - Basic earnings per share (EPS) decreased by 27.81% to 1.09 yuan per share[121] - Weighted average return on equity (ROE) dropped by 10.23 percentage points to 11.55%[121] Cash Flow and Financing Activities - The company's cash and cash equivalents increased by 238,239,548.75 RMB, reaching a total of 2,307,768,991.53 RMB at the end of the period[98] - The company's short-term borrowing increased by 100,000,000.00 RMB, with a total of 100,072,222.22 RMB at the end of the period[96] - The company's total investment in financial products was 1,798,000,000.00 RMB, an increase from the previous period's 1,622,010,000.00 RMB[94] - The company's total cash outflow related to leasing activities was 3,383,139.22 RMB[105] - The company's total cash outflow related to financing activities was 3,171,139.22 RMB, a significant decrease from the previous period's 30,315,099.62 RMB[95] - The company's total cash outflow related to investment activities was 1,798,000,000.00 RMB, an increase from the previous period's 1,622,010,000.00 RMB[94] - The company's total cash outflow related to operating activities was 729,212,499.59 RMB, an increase from the previous period's 606,613,170.14 RMB[98] - The company's total cash outflow related to the payment of dividends was 310,823,800.00 RMB[96] - The company's total cash outflow related to the payment of IPO issuance fees was 26,602,479.62 RMB in the previous period[95] Expenses and Costs - Total management expenses decreased to 136,349,813.27 RMB from 144,180,344.74 RMB, a reduction of 5.4%[53] - R&D expenses increased to 111,964,592.30 RMB from 89,462,842.32 RMB, a growth of 25.1%[54] - Government subsidies decreased to 47,390,378.61 RMB from 53,254,038.41 RMB, a reduction of 11.0%[55] - Investment income from bank financial products decreased to 2,454,302.84 RMB from 4,653,541.60 RMB, a reduction of 47.3%[56] - Interest income increased significantly to 74,460,498.56 RMB from 16,251,609.72 RMB, a growth of 358.2%[56] - Credit impairment losses slightly decreased to 3,159,494.22 RMB from 3,233,939.87 RMB, a reduction of 2.3%[59] - Asset impairment losses increased to -12,363,832.71 RMB from -4,157,876.36 RMB, a significant increase in losses[60] - Current income tax expense increased to 111,841,440.48 RMB from 100,786,018.29 RMB, a growth of 11.0%[63] - Total employee compensation increased to 80.16 million yuan from 74.19 million yuan, a rise of 8.05%[107] - Direct material costs rose to 7.26 million yuan from 5.29 million yuan, an increase of 37.25%[107] - Depreciation and amortization expenses surged to 12.35 million yuan from 2.98 million yuan, a significant jump of 315.08%[107] - Other expenses increased to 12.19 million yuan from 7.01 million yuan, up by 73.96%[107] - Total expenses for the period amounted to 111.96 million yuan, up from 89.46 million yuan, a 25.15% increase[107] Market and Industry Analysis - The vitamin industry faced challenges with slowing global economic growth and increased competition[128] - The company achieved domestic registration approval for folic acid raw materials and obtained EU export certification for Vitamin D3 raw materials[129] - The company completed multiple quality system expansion certifications, including ISO22000 for cholesterol and FAMI-QS certification for Vitamin A acetate and 25-hydroxy Vitamin D3[129] - R&D expenses continued to grow rapidly, driving continuous improvement in production levels[130] - The company is steadily advancing projects such as Vitamin A, Vitamin B5, and Ningxia Tianxin, ensuring sustainable development[130] - China's vitamin production in 2023 is expected to reach 434,000 tons, a 4.0% year-on-year increase, accounting for 84.4% of global production[134] - The Chinese vitamin market value in 2023 is projected to be $3.72 billion, a 16.4% year-on-year decrease[134] - The company holds a leading global market share in Vitamin B6 and Vitamin B1, and is in the top tier for biotin and folic acid products[135] - The company has established a strong global competitiveness in B-group vitamins, including Vitamin B6, Vitamin B1, biotin, and folic acid[136] - The company's ABL product, used in pesticide intermediates and Vitamin B1, achieved external sales in 2022 and further expanded in 2023[136] - Vitamin business accounted for 96.30% of the company's main business revenue in 2023, being the primary factor affecting performance fluctuations[141] - Overall downstream demand for vitamins was weak in 2023, leading to increased competitive pressure on the supply side and suppressed prices, contributing to the company's performance decline[141] Corporate Governance and Compliance - The company established Tianxin International Holdings (Hong Kong) Limited in March 2023 with a registered capital of 10,000 HKD[109] - As of December 31, 2023, Tianxin International Holdings (Hong Kong) Limited reported a net loss of 92,783.10 yuan[109] - The company's subsidiary, Ningxia Tianxin Pharmaceutical Co., Ltd., transferred 10,000 yuan of equity in Qingtongxia Tianxin Dingheng Heating Power Co., Ltd., reducing its indirect ownership from 100% to 99.75%[113] - The company's stock is listed on the Shanghai Stock Exchange under the ticker symbol 603235[116] - The company's auditor is Zhonghui Certified Public Accountants, and its continuous supervision sponsor is CITIC Securities[117] - The company's environmental management system is established and maintained in accordance with ISO14001 standards, emphasizing green development and circular economy[143][147] - The company has a comprehensive sales and service network centered in Shanghai, covering Asia, Europe, North America, South America, Oceania, and Africa[148] - The company has obtained various certifications, including FAMI-QS, ISO22000, BRC, Halal, Kosher, and certifications from regulatory bodies in China, the EU, the US, and Japan, ensuring access to high-end markets[149] Debt and Liabilities - The company's debt-to-asset ratio increased to 16.84% as of December 31, 2023, compared to 13.29% in the previous year[163] - Short-term borrowings: RMB 10,104.00 (within one year)[161] - Accounts payable: RMB 12,663.93 (within one year)[161] - Other payables: RMB 857.85 (within one year)[161] - Non-current liabilities due within one year: RMB 312.37[161] - Lease liabilities: RMB 530.04 (total)[162] - Total financial liabilities and contingent liabilities: RMB 25,611.19 (current period) vs RMB 12,783.00 (previous period)[162] - The company's other payables decreased from RMB 10,548,296.39 at the beginning of the period to RMB 8,578,504.58 at the end of the period[173] - The company's non-bank acceptance bills endorsed but not yet due decreased from RMB 60,012,793.35 at the beginning of the period to RMB 50,489,814.34 at the end of the period[177] - The company's government grants increased from RMB 306,156,569.99 at the beginning of the period to RMB 390,788,063.48 at the end of the period, with an increase of RMB 115,419,200.00 and a decrease of RMB 30,787,706.51 during the period[180] - The company's lease liabilities due within 1 year decreased from RMB 3,419,674.54 at the beginning of the period to RMB 3,123,735.24 at the end of the period[176] - The company's long-term payables increased from RMB 4,646,387.50 at the beginning of the period to RMB 5,095,912.47 at the end of the period[178] - The company's prepaid taxes to be transferred decreased from RMB 1,613,296.80 at the beginning of the period to RMB 1,016,999.16 at the end of the period[177] - The company's deposit and guarantee liabilities increased from RMB 175,000.00 at the beginning of the period to RMB 225,000.00 at the end of the period[175] Related Party Transactions - The company's total related party transactions amounted to RMB 3,006.56 million, with the majority coming from sales to related parties at RMB 2,105.95 million[47] - The company's subsidiaries and related parties include Zhejiang Tianxin Pharmaceutical Co., Ltd., Zhejiang Xinweishi Biotechnology Co., Ltd., and Shanghai Newrite Biotechnology Co., Ltd., among others[171] Research and Development - R&D expenses increased by 25.15% to RMB 111,964,592.30, reflecting increased investment in research and development[183] - The company's R&D expense ratio continued to increase during the reporting period, with projects such as Vitamin B5, Vitamin A, and Ningxia Tianxin progressing as planned[142] - The company's production sites have passed FDA certification, and Vitamin B6 and Vitamin B1 (hydrochloride) have obtained FDA DMF filings[143] Sales and Distribution - The company's sales model is primarily direct sales, with distributors handling wholesale or retail[140] - Main business revenue for 2023 was RMB 1,851,390,100, a decrease of 17.83%, mainly due to lower vitamin product prices[185] - Main business costs for 2023 were RMB 1,135,447,100, a decrease of 18.98%, driven by lower raw material prices and reduced manufacturing expenses[185] - Contract liabilities decreased to RMB 21,098,771.55 from RMB 23,341,621.74, indicating a reduction in prepayments from customers[196] Taxation and Deferred Taxes - Deferred tax assets and liabilities are recognized based on temporary differences between book value and tax base, with certain exceptions for transactions not affecting accounting profit or taxable income[8] - The company's internal transactions resulted in unrealized profits of RMB 126,804,672.87, with deferred tax assets of RMB 19,020,700.93[40] - The company's bad debt provision decreased by RMB 3,155,511.19, resulting in a deferred tax asset reduction of RMB 471,116.80[39] - The company's unconfirmed deferred tax assets increased by RMB 21,338,495.70, primarily due to deductible losses of RMB 17,651,718.49[45] - Deferred tax liabilities at the end of the period were RMB 4,179,272.04, primarily due to accelerated depreciation of fixed assets amounting to RMB 2,278,177.38[42] Other Financial Metrics - The total balance of deposits, guarantees, and other receivables decreased from RMB 4.27 million to RMB 2.44 million year-over-year[18] - The provision for bad debts decreased by RMB 1.5 million, resulting in a year-end balance of RMB 738,295.84[21] - The company's long-term prepaid expenses decreased by RMB 1,385,837.04, with the hazardous waste treatment center opening fee being the largest component at RMB 8,021,289.

证券代码：603235 证券简称：天新药业 公告编号：2024-022 江西天新药业股份有限公司 关于 2023 年第四季度经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号——行 业信息披露》的相关规定，现将江西天新药业股份有限公司（以下简称"公司"） 2023 年第四季度经营数据（未经审计）公告如下： 一、 2023年第四季度主要经营数据 1、主营业务分产品情况 单位：元 币种：人民币 | 产品分类 | 年 2023 | 月收入 10-12 | 2022 | 年 10-12 | 月收入 | 同比变动 | | --- | --- | --- | --- | --- | --- | --- | | 族维生素 B | | 340,482,219.84 | | 457,578,871.42 | | -25.59% | | 其他维生素 | | 35,227,716.90 | | 60,543,528.69 | | -41.81% | | 精细化工品 | | ...

联系电话：0798-6709288 公司网址：www.txpharm.com 公司地址：江西景德镇乐平市乐安江工业园（工业六路） 股票代码：603235 江西天新药业股份有限公司 2023 年度 环境、社会及治理（ESG）报告 CONTENTS 目录 关于本报告 董事长致辞 公司概况 公司简介 组织架构 发展历程 企业文化 公 司 简 介 组 织 架 构 发 展 历 程 企 业 文 化 专题聚焦 专 题 聚 焦 创新天新 突破永无止境 发展天新 成就薪火相传 创 新 天 新 突 破 永 无 止 境 发 展 天 新 成 就 薪 火 相 传 01 精心运营 完善治理 | 建 | 立 | 现 | 代 | 法 | 人 | 治 | 理 | 结 | 构 | 1 | 3 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 完 | 善 | 科 | 学 | 决 | 策 | 机 | 制 | | | 1 | 3 | | 提 | 升 | 信 | 息 | 披 | 露 | 质 | 量 | | | 1 | 3 | | 0 | 2 | 安 ...

二、独立董事年度履职概况 （一）出席董事会情况 | 本人出席次数 | | --- | | 报告期内 | | 公司报告期 委托出席次数 缺席次数 是否连续两 | 江西天新药业股份有限公司 2023 年度独立董事述职报告 作为江西天新药业股份有限公司（以下简称"公司"）的独立董事，本人严 格按照《公司法》《证券法》《上市公司独立董事管理办法》等法律法规以及《江 西天新药业股份有限公司章程》（以下简称"《公司章程》"）《江西天新药业股份 有限公司独立董事工作制度》（以下简称"《独立董事工作制度》"）的有关规定， 本着客观、公正、独立的原则，及时了解公司的生产经营及发展状况，积极出席 公司董事会、董事会专门委员会和股东大会，认真审议公司各项议案，对公司生 产经营和业务发展提出合理的建议，有效维护了公司整体利益和全体股东，尤其 是中小股东的合法权益。 现将本人 2023 年度（以下简称"报告期"）履行独立董事职责情况报告如下： 一、独立董事的基本情况 刘桢：出生于 1973 年 6 月，中国国籍，无境外永久居留权，硕士研究生学 历，注册会计师。1994 年 8 月至 2007 年 1 月历任立信会计师事务所审计员、部 ...

1 / 9 第一条 为了规范江西天新药业股份有限公司（下称"公司"）募集资金的使 用和管理，最大程度地保障投资者的利益，依据《中华人民共和国公 司法》《中华人民共和国证券法》《上市公司证券发行注册管理办法》 《上市公司监管指引第2号——上市公司募集资金管理和使用的监管 要求》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 （以下简称《自律监管指引第 1 号》）等有关法律、行政法规和规范 性文件及《江西天新药业股份有限公司章程》（下称"公司章程"）的 规定制定本制度。 第二条 本制度所称募集资金，是指公司通过发行股票及其衍生品种，向投资 者募集并用于特定用途的资金。 第三条 公司董事会应建立募集资金存储、使用和管理的内部控制制度，对募 集资金存储、使用、变更、监督和责任追究以及募集资金使用的申请、 分级审批权限、决策程序、风险控制措施及信息披露程序等内容进行 明确规定。 江西天新药业股份有限公司 募集资金管理制度 江西天新药业股份有限公司 募集资金管理制度 第一章 总则 公司应当将募集资金存储、使用和管理的内部控制制度及时报证券交 易所备案并在证券交易所网站上披露。 第四条 公司的董事、监事和高级 ...

江西天新药业股份有限公司 年度募集资金存放与使用情况鉴证报告 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5-8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road. Qianjiang New City, Hangzhou www.zhcpa.cn Tel. 0571-88879999 Fax. 0571-88879000 目 录 | | 页 次 | | --- | --- | | 一、年度募集资金存放与使用情况鉴证报告 | 1-3 | | 二、江西天新药业股份有限公司关于 2023 年度募集资金 | | | 存放与实际使用情况的专项报告 | 4-12 | 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5-8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 www ...

江西天新药业股份有限公司 公司章程 江西天新药业股份有限公司 章程 二〇二四年四月 | 目录 | | --- | | 第一章 | 总则 1 | | --- | --- | | 第二章 | 经营宗旨和范围 2 | | 第三章 | 股份 2 | | 第一节 | 股份发行 2 | | 第二节 | 股份增减和回购 3 | | 第三节 | 股份转让 4 | | 第四章 | 股东和股东大会 5 | | 第一节 | 股东 5 | | 第二节 | 股东大会的一般规定 7 | | 第三节 | 股东大会的召集 10 | | 第四节 | 股东大会的提案与通知 11 | | 第五节 | 股东大会的召开 13 | | 第六节 | 股东大会的表决和决议 16 | | 第五章 | 董事会 20 | | 第一节 | 董事 20 | | 第二节 | 董事会 23 | | 第三节 | 董事会秘书 29 | | 第四节 | 高级管理人员 30 | | 第六章 | 监事会 32 | | 第一节 | 监事 32 | | 第二节 | 监事会 32 | | 第七章 | 财务会计制度、利润分配和审计 34 | | 第一节 | 财务会计制度 34 | | 第 ...

公司代码：603235 公司简称：天新药业 江西天新药业股份有限公司 2023 年度内部控制评价报告 江西天新药业股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能 ...

证券代码：603235 证券简称：天新药业 公告编号：2024-016 江西天新药业股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：中汇会计师事务所（特殊普通合伙）（以 下简称"中汇会计师事务所"）。 本事项尚需提交股东大会审议。 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、基本信息 中汇会计师事务所，于 2013 年 12 月转制为特殊普通合伙，管理总部设立于 杭州，系原具有证券、期货业务审计资格的会计师事务所之一，长期从事证券服 务业务。 事务所名称：中汇会计师事务所（特殊普通合伙） 成立日期：2013 年 12 月 19 日 注册地址：浙江省杭州市上城区新业路 8 号华联时代大厦 A 幢 601 室 首席合伙人：余强 上年度末（2023 年 12 月 31 日）合伙人数量：103 人 上年度末（2023 年 12 月 31 日）注册会计师人数：701 人 上年度末（2023 年 12 月 31 日）签署过证券服务业务审计报告的注 ...

作为江西天新药业股份有限公司（以下简称"公司"）的独立董事，本人到 任后，严格按照《公司法》《证券法》《上市公司独立董事管理办法》等法律法规 以及《江西天新药业股份有限公司章程》（以下简称"《公司章程》"）《江西天新 药业股份有限公司独立董事工作制度》（以下简称"《独立董事工作制度》"）的有 关规定，本着客观、公正、独立的原则，及时了解公司的生产经营及发展状况， 积极出席公司董事会、董事会专门委员会和股东大会，认真审议公司各项议案， 对公司生产经营和业务发展提出合理的建议，有效维护了公司整体利益和全体股 东，尤其是中小股东的合法权益。 现将本人 2023 年度（以下简称"报告期"）履行独立董事职责情况报告如下： 一、独立董事的基本情况 刘路遥：出生于 1987 年 4 月，中国国籍，无境外永久居留权，硕士研究生 学历，中国注册会计师，特许金融分析师。2012 年 7 月至 2018 年 6 月历任中国 国际金融股份有限公司投资银行部经理、高级经理、副总经理；2018 年 7 月至 2021 年 2 月任 BitMain Technologies Holding Company 首席财务官；2021 年 2 月 ...